Patrick Soon

Insider Reports History

Entity
Individual
Location
9922 Jefferson Boulevard, Culver City, CA
Signature
/s/ Patrick Soon-Shiong, /s/ Charles Kenworthy, Manager of MP 13 Ventures, on behalf of itself and as General Partner of Cambridge Equities, and /s/ Charles Kenworthy, Manager of California Capital Equity, and Manager of Nant Capital
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Patrick Soon:

Stock Role Class Num Shares Value Price $ Report Date Ownership
ImmunityBio, Inc. Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner Common Stock 246M $562M $2.28 Dec 10, 2024 Indirect
ImmunityBio, Inc. Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner Common Stock 29.5M $67.2M $2.28 Dec 10, 2024 Direct
NantHealth, Inc. Chief Executive Officer, Director, 10%+ Owner Common Stock 15.9M $31.2M $1.96 Aug 28, 2023 Indirect
ImmunityBio, Inc. Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner Common Stock 7.98M $18.2M $2.28 Dec 10, 2024 See footnte
ImmunityBio, Inc. Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner Restricted Stock Units 343K $1.39M $4.04 Feb 22, 2024 Direct
ImmunityBio, Inc. Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner Stock Option (right to buy) 1.19M Feb 22, 2024 Direct
ImmunityBio, Inc. Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner Amended and Restated Promissory Note $0 Dec 10, 2024 Indirect
ImmunityBio, Inc. Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner Convertible Promissory Note $0 Dec 10, 2024 Indirect
ImmunityBio, Inc. Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner Second Amended and Restated Convertible Promissory Note $505M Dec 10, 2024 Indirect

Insider Reports Filed by Patrick Soon

Symbol Company Period Transactions Value $ Form Type Date Filed Role
IBRX ImmunityBio, Inc. Dec 10, 2024 6 $126M 4 Dec 12, 2024 Founder, Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
IBRX ImmunityBio, Inc. Feb 22, 2024 2 $0 4 Feb 26, 2024 Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
IBRX ImmunityBio, Inc. Dec 29, 2023 2 $410M 4 Jan 3, 2024 Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
IBRX ImmunityBio, Inc. Sep 11, 2023 9 $200M 4 Sep 13, 2023 Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
NHIQ NantHealth, Inc. Aug 28, 2023 2 $16M 4 Aug 30, 2023 Chief Executive Officer, Director, 10%+ Owner
IBRX ImmunityBio, Inc. May 12, 2023 1 $30.5M 4 May 16, 2023 Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
IBRX ImmunityBio, Inc. Dec 12, 2022 2 -$5 4 Dec 14, 2022 Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
IBRX ImmunityBio, Inc. Aug 31, 2022 6 $315M 4 Nov 8, 2022 Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
IBRX ImmunityBio, Inc. Mar 23, 2022 2 $0 4 Mar 25, 2022 Executive Chairman, Director, 10%+ Owner
NHIQ NantHealth, Inc. Sep 9, 2021 1 $0 4 Sep 13, 2021 Chairman and CEO, Director, 10%+ Owner
IBRX ImmunityBio, Inc. Jun 10, 2021 1 $0 4 Jun 14, 2021 Executive Chairman, Director, 10%+ Owner